Comparison of two epoetin brands in anemic hemodialysis patients: Results of two efficacy trials and a single-dose pharmacokinetic study

Fundamental and Clinical Pharmacology

Volumn 20, Issue 5, 2006, Pages 493-502

  Milutinović, Slobodan ^a   Plavljanić, Duro ^a   Trkulja, Vladimir ^b  

^a Croatian Academy of Medical Sciences   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Efficacy; Pharmacokinetics; Recombinant human erythropoietin

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPOETIN OMEGA; EPOMAX; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIABETIC FOOT; DIARRHEA; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; EPISTAXIS; FEMALE; FISTULA; GASTROINTESTINAL HEMORRHAGE; HEART FAILURE; HEMODIALYSIS; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; INFLAMMATION; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; METRORRHAGIA; NEUTROPENIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RECTUM HEMORRHAGE; SEPTIC SHOCK; THROMBOSIS; TREATMENT OUTCOME;

ANEMIA; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; EPOETIN ALFA; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 33745188116     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2006.00433.x     Document Type: Article

References (16)

1. Fisher J.W. Erythropoietin: physiology and pharmacology update. Exp. Biol. Med. (2003) 228 1-14.
2. Deicher R., Horl W.H. Differentiating factors between erythropoiesis-stimulating agents: a guide to selection for anemia of chronic kidney disease. Drugs (2004) 64 499-509.
3. Storring P.L., Tiplady R.J., Gaines Das R.E. et al. Epoetin alpha and beta differ in their erythropoietin isoform compositions and biological properties. Br. J. Haematol. (1998) 100 79-85
4. Powell J.S., Berkner K.L., Lebo R.V., Adamson JW. Human erythropoietin gene: high level expression in stably transfected mammalian cells and chromosome localization. Proc. Natl. Acad. Sci. USA (1986) 83 6465-6469.
5. Mueller P.P., Schlenke P., Nimtz M., Conradt H.S., Hauser H. Recombinant glycoprotein product quality in proliferaton-controlled BHK-21 cells. Biotech. Bioeng. (1999) 65 529-536.
6. Nimtz M., Martin W., Wray V., Kloppel KD., Augustin J., Conradt HS. Structures of sialylated oligosaccharides of human erythropoietin expressed in recombinant BHK-21 cells. Eur. J. Biochem. (1993) 213 39-56.
7. Skibelli V., Nissen-Lie G., Torjesen P. Sugar profiling proves that serum erythropoietin differs from recombinant human erythropoietin. Blood (2001) 98 3626-3634.
8. Bren A., Kandus A., Varl J. et al. A comparison between epoetin omega and epoetin alpha in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study. Artif. Organs (2002) 26 91-96.
9. AAMI. American national standards for hemodialysis systems, AAMI Standards and recommended practices, (volume 3): Dialysis. AAMI, Arlington, VA, 1993, pp. 35-54.
10. The European Department for the Quality of Medicines. Water for diluting concentrated hemodialysis solutions, in: Schnadelbach D. (Ed.), European pharmacopoeia (3rd edition), The European Department for the Quality of Medicines, Council of Europe, Strasbourg, 1997, pp. 923-925.
11. Anonymous. European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol. Dial. Transplant. (1999) 14 (Suppl. 5) 1-50.
12. Locatelli F., Baldamus C.A., Villa G., Ganea A., Martin Francisco de A.L. Once-weekly compared to three-times-weekly subcutaneous epoetin beta: results from a randomized, multicenter, therapeutic-equivalence study. Am. J. Kidney Dis. (2002) 40 119-125.
13. Richardson D. Clinical factors influencing sensitivity and response to epoetin. Nephrol. Dial. Transplant. (2002) 17 (Suppl. 1) 53-59.
14. European Medicines Evaluation Agency. Guidance on biosimilar medicinal products containing recombinant erythropoietins. Committee for Human Medicinal Products, European Medicines Evaluation Agency, London, 2005, p. 4.
15. Romanowski R.R., Sytkowski A.J. The molecular structure of human erythropoietin. Hematol. Oncol. Clin. North. Am. (1994) 8 885-894.
16. Storring P.L., Gaines-Das R.E. The international standard for recombinant DNA-derived erythropoietin: collaborative study of four recombinant DNA-derived erythropoietins and two highly purified urinary erythropoietins. J. Endocrinol. (1992) 124 459-484.